Sarepta Therapeutics Inc (SRPT)
127.39
+3.14
(+2.53%)
USD |
NASDAQ |
Apr 25, 16:00
127.36
-0.03
(-0.02%)
After-Hours: 20:00
Sarepta Therapeutics Gross Profit (TTM): 1.093B for Dec. 31, 2023
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 1.093B |
September 30, 2023 | 968.02M |
June 30, 2023 | 863.54M |
March 31, 2023 | 832.12M |
December 31, 2022 | 793.02M |
September 30, 2022 | 735.11M |
June 30, 2022 | 710.76M |
March 31, 2022 | 659.64M |
December 31, 2021 | 604.84M |
September 30, 2021 | 557.86M |
June 30, 2021 | 520.80M |
March 31, 2021 | 500.25M |
December 31, 2020 | 476.72M |
September 30, 2020 | 438.53M |
June 30, 2020 | 395.62M |
March 31, 2020 | 350.35M |
December 31, 2019 | 324.25M |
September 30, 2019 | 310.98M |
June 30, 2019 | 294.72M |
March 31, 2019 | 282.77M |
December 31, 2018 | 266.84M |
September 30, 2018 | 249.29M |
June 30, 2018 | 222.42M |
March 31, 2018 | 190.13M |
December 31, 2017 | 147.23M |
Date | Value |
---|---|
September 30, 2017 | 98.82M |
June 30, 2017 | 55.94M |
March 31, 2017 | 21.44M |
December 31, 2016 | 5.32M |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 | |
December 31, 2011 | |
September 30, 2011 |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
294.72M
Minimum
Jun 2019
1.093B
Maximum
Dec 2023
601.59M
Average
557.86M
Median
Sep 2021
Gross Profit (TTM) Benchmarks
PTC Therapeutics Inc | 872.34M |
Vertex Pharmaceuticals Inc | 8.607B |
Regenxbio Inc | 53.03M |
CytomX Therapeutics Inc | -- |
Apellis Pharmaceuticals Inc | 338.08M |